Dean Emeritus Timothy Chan
IS MOVING ON
Dean Vanderveen, Vice Dean Sarah Hamm-Alvarez and Dean Emeritus Chan.
on the grant
front
On June 8, Dean Vanderveen and Vice Dean Sarah HammAlvarez hosted a celebration honoring Dean Emeritus Timothy Chan upon his retirement. Dean Chan joined the USC School of Pharmacy in 1981 as an associate professor, rising to a full professor, founding chair of the Department of Molecular Pharmacology and Toxicology, and ultimately assuming the deanship in 1995. Dean Chan served ten years as dean, and has continued as a professor at the School since that time. Faculty spoke at the event, noting his support and mentorship during his dean tenure. Dean Vanderveen mentioned the grace with which Dean Chan pursued his many roles at the School and Vice Dean Hamm-Alvarez, the Gavin S. Herbert Professor in Pharmaceutical Sciences, noted that Dean Chan was instrumental in her development as a professor and as a leader. University Professor Jean Shih, the Boyd P. and Elsie D. Welin Professor in Pharmaceutical Science, summed it all up by saying, “Dean Chan always showed us the path.”
Roberta Diaz Brinton, R. Pete Vanderveen Chair in Therapeutic Discov-
Andrew MacKay, has received a CTSI multidisciplinary grant in the
ery and Development, has received a renewal of the program project grant
amount of $80,000 to conduct a preclinical evaluation of disintegrins for
focusing on perimenopause in brain aging and Alzheimer’s disease, from the
cancer therapy. Using genetic engineering, the project aims to leverage
National Institutes of Health. The renewal amount is $1.7 million for a 5-year
USC-developed expertise to optimize these anti-cancer pharmaceuticals
term. Brinton is the principal investigator on the project with co-investi-
and to lay the groundwork for a larger NIH project. A team from the Keck
gators Liqin Zhao and Enrique Cadenas, Charles Krown Pharmacy Alumni
School of Medicine are co-investigators on the project; the Department of
Professor in Pharmaceutical Sciences.
Defense has awarded MacKay a grant in the amount of $250,000 to explore new approaches to treat corneal injury using targeted biopharmaceuticals.
Jean C. Shih, University Professor and the Boyd P. and Elsie D. Welin
Co-investigator is Sarah Hamm-Alvarez.
Professor in Pharmaceutical Sciences, is the primary investigator on a 3-year, $579,449 grant from the Department of Defense. The project is entitled
Clay Wang has received renewal funding for the program project grant,
“Monoamine Oxidase A: A Novel Target for Progression and Metastasis of
“Identification of Secondary Metabolites and Biosynthesis Pathways
Prostate Cancer.” Co-investigator is Bogdan Olenyuk.
in A. Nidulans,” from the National Institutes of Health. Wang is a coinvestigator with the project’s primary investigator, Berl Oakley, at the University of Kansas.
summer-fall 2012 | USC PHARMACY MAGAZINE
27